Dillon & Associates’s Eli Lilly LLY Stock Holding History

Dillon & Associates’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$16.1M	Buy	13,895 +1,802	+15%	+$2.13M	1.89%	14
2026 Q2	$14.5M	Buy	12,093 +3,142	+35%	+$3.21M	1.77%	18
2026 Q1	$8.24M	Buy	8,951 +1,840	+26%	+$1.87M	1.13%	23
2025 Q4	$7.64M	Buy	7,111 +1,138	+19%	+$1.09M	0.99%	26
2025 Q3	$4.56M	Buy	5,973 +1,745	+41%	+$1.3M	0.59%	35
2025 Q2	$3.3M	Buy	4,228 +1,706	+68%	+$1.33M	0.45%	38
2025 Q1	$2.08M	Buy	2,522 +1,276	+102%	+$1.06M	0.31%	44
2024 Q4	$962K	Buy	1,246 +794	+176%	+$657K	0.13%	56
2024 Q3	$400K	Hold	452	–	–	0.06%	66
2024 Q2	$409K	Hold	452	–	–	0.06%	67
2024 Q1	$352K	Hold	452	–	–	0.06%	69
2023 Q4	$264K	Sell	452 -19	-4%	-$11.1K	0.05%	73
2023 Q3	$253K	Buy	471 +20	+4%	+$10.3K	0.05%	72
2023 Q2	$212K	Buy	+451	New	+$189K	0.04%	77

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $104B AUM 51.65% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Sapient Capital Indianapolis, Indiana $7.44B AUM 23.27% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $39.3B AUM 31.81% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Old National Bancorp Evansville, Indiana $5.07B AUM 22.07% 1-Year Est. Return

Dillon & Associates's LLY Position: Q3 2026 in Review

Dillon & Associates increased its Eli Lilly (LLY) stake by 15% in Q3 2026, buying an estimated $2.13M and bringing the position to 13,895 shares worth $16.1M. The position accounts for 1.89% of the portfolio, ranked #14.

Dillon & Associates first reported a position in LLY in Q2 2023 and has held it in 14 quarters since. 2,091 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

Dillon & Associates held 13,895 shares of Eli Lilly worth $16.1M as of Q3 2026.
Dillon & Associates bought 1,802 Eli Lilly shares in Q3 2026, an estimated $2.13M.
Eli Lilly made up 1.89% of Dillon & Associates's portfolio in Q3 2026, its #14 holding.
Dillon & Associates first reported a position in Eli Lilly in Q2 2023 and has held it in 14 quarters since.
2,091 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Dillon & Associates's 13F filing for Q3 2026, filed 22 Oct 2026.